Immune Therapy Articles & Analysis
50 news found
Compared with conventional formulations, microspheres enable long-term and stable drug release in the body, making them a perfect choice for immunization, gene therapy and tumor chemotherapy. “With the increasing demand for targeted drug delivery and minimally invasive procedures, there is a growing need for high-quality polymer microspheres and raw ...
(NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors in combination with immune checkpoint inhibitor (ICI) ...
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. ...
Her revolutionary work has supported multiple clinical trials with cancer therapies, prophylactic vaccines, and development of antibody therapies. ...
ByArdigen
Agnieszka Blum, MD, PhD will continue her mission as the General Director of the Immunology Business Unit at Ardigen, where she focuses on developing AI platforms to solve therapy development problems in cell therapies, cancer vaccines, and TCR-mimicking antibodies. ...
ByArdigen
This further expands the GlycoConnect™ ADC tool kit by significantly enhancing the versatility across cytotoxic payloads and supports further expansion into antibody-based targeted gene therapy and immune cell engager ...
“Chris brings a wealth of industry experience to Immune-Onc at an exciting stage in the company’s evolution,” said Charlene Liao, Ph.D., chief executive officer of Immune-Onc. ...
It is a state-of-the-art manufacturing facility custom built to collaborate with the biotech industry to advance cutting-edge cell and gene therapies. T-cell therapies utilize immune cells that are genetically modified to fight cancer. The modified cells are infused into the patient with the goal of fighting the cancer and creating long-term ...
“Similar to the Ardigen team, I have dedicated my career to immuno-oncology with special interest in cellular therapy. I strongly believe that this modality has great curative potential and will give hope to terminally-ill patients. ...
ByArdigen
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cells Patent portfolio broadly covers chemotherapy resistant engineering of innate immune cells for cellular therapy, providing the basis for IN8bio’s Drug Resistant ...
“This advisory board brings together invaluable expertise in hematological and solid cancers as well as the biology of NK cells and their application to further the development of our novel and highly potent innate immune cell-engaging therapies.” Dr. Fehniger of Washington University School of Medicine added, “This is an exciting time for ...
“It is widely acknowledged that targeting CD123 holds significant untapped promise in developing better AML therapies. We believe our differentiated approach in targeting CD123 has the potential to provide a novel, innate immune system-engaging therapy to improve clinical outcomes,” said Dr. ...
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector therapy induces greater immune response than single-vector therapy in preclinical setting and translates into significant reduction of ...
The International Society for Cell & Gene Therapy (ISCT) and The National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT) led by the Georgia Institute of Technology are pleased to launch the first joint-training program of our partnership, Workforce Development in Biomanufacturing – A Global Partnership with ISCT and CMaT. ...
New research has investigators seeking to demonstrate the safety profile of a cannabinoid formulation, when given to glioblastoma patients in conjunction with standard-of-care therapy. Immunotherapy, using therapies to ramp up a patient’s own immune system to fight cancer has been very successful in the treatment of melanoma and lung ...
AFM24 utilizes the patient’s innate immunity to redirect and activate immune cells, overcoming resistance to current therapies. ...
The analysis also showed activation of cytotoxic T cells in the periphery, and infiltration of T cells into the tumor bed, suggesting stimulation of anti-cancer immunity beyond the innate immune system and the possible engagement of the adaptive immune system. These data support the rationale for AFM24 as monotherapy and the two combinations that ...
The company has received the IND clearance in China and plans to evaluate IO-108 in solid tumors in China in 2H 2022. ABOUT IMMUNE-ONC THERAPEUTICS, INC. Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint ...
(NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases. OPKO acquired ModeX for $300 million in OPKO common stock. ...
IO-106 is the third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer The Company will present a scientific poster at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic ...